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Glycodendropeptides stimulate dendritic cell
maturation and T cell proliferation: a potential
influenza A virus immunotherapy†
Ainhoa Mascaraque,a Wioleta Kowalczyk,b Tahia Fernández,c Francisca Palomares,c
Cristobalina Mayorga,*c David Andreu*b and Javier Rojo*a
Mannosylation facilitates uptake and internalization of immunogenic peptides by antigen-processing cells
expressing mannose receptors at their surface, such as DC-SIGN, a lectin that plays a key role in the
immune response against different pathogens. This internalization, processing and subsequent MHC pre-
sentation may result in a strong T cell stimulation. Here, we hypothesized that combining mannose
glycodendrons with multivalent presentation of peptide epitopes in a likewise dendron format would yield
hybrid constructs, named glycodendropeptides (GDPs), with the capacity to enhance peptide immunoge-
nicity, hence providing a novel and versatile platform for applications in immunotherapy. Thus, GDPs of dif-
ferent valencies displaying the NP366–374 epitope, a conserved sequence from the influenza A virus nucleo-
protein (NP), have been built by two click chemistry-based methodologies and assessed as potential flu
vaccine candidates. Preliminary evaluation of the ability of these constructs to stimulate dendritic cell mat-
uration and lymphocyte proliferation was promising, showing the highest-functionalized NP366–374 GDPs as
inducing the strongest immunostimulatory effect.
Introduction
The biological effect of peptide or protein mannosylation,1
which induces a receptor dependent internalization process
in dendritic cells (DCs) and ensues strong T cell stimulation,
constitutes an interesting tool for developing novel strategies
in the vaccine field.2
Compared to the entire protein immunogens, peptides
show clear advantages such as stringent chemical definition,
fast and efficient large scale production, or simple (cold
chain-free) transport and storage.3 These advantages, how-
ever, can be offset by the relatively poor immunogenicity of
peptides, a limitation often overcome by multiple presenta-
tions of the peptide antigen, such as the dendrimer systems
pioneered by Tam named multiple antigen peptides (MAP).4
Our group has recently described hybrid constructs named
glycodendropeptides (GDPs), where the multivalency of
peptide epitopes in a MAP format combined with the
improved uptake facilitated by mannosylation may lead to
enhanced immunogenicity.5 Specifically, mannosylation
would induce MAP internalization into DCs through interac-
tions with the DC-SIGN (dendritic cell-specific intercellular
adhesion molecule-3-grabbing non-integrin) receptor,6 a lec-
tin expressed at the surface of immature DCs (imDCs).
This receptor is involved in the internalization of highly
mannosylated antigens to be processed and presented to T
cells to elicit an immune response.7 Recently, we have shown
that a dendron functionalized with nine copies of mannose
(Man) has the ability to interact, in a sugar dependent man-
ner, with DC-SIGN and become internalized into DCs.8 In
this context, the nonavalent glycodendron 1 (Scheme 1) was
selected as the carbohydrate moiety of the GDPs used in the
present study, although other Man valencies could be easily
examined as well.
Two different synthetic approaches (methods A and B,
Scheme 1)5 provide efficient and convergent routes to chemi-
cally well-defined GDPs that combine, in a single platform,
multiple carbohydrate and peptide epitopes. The modularity
and versatility of these routes allow a variety of biological
applications where both the carbohydrate and the peptide, as
well as their respective valencies, can be selected at will.
Influenza A is one of the most important respiratory
pathogens worldwide, with vaccination being the widely
accepted way to control the disease.9 However, in contrast
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to other pathogens that require vaccination only a few
times in a lifetime, influenza vaccines have to be adminis-
tered yearly. This is due to the remarkable mutation rates –
and ensuing antigenic variability – of the two main enve-
lope proteins, hemagglutinin (HA) and neuraminidase (NA),
that up to now constitute the cornerstone of practically all
influenza vaccines. It has been argued, however, that viral
proteins with much lower yearly mutation rates could serve
as better immunogens in a future universal flu vaccine.10
One such highly conserved protein is the nucleoprotein
(NP) that encapsidates the viral RNA; in particular, the
nine-residue epitope NP366–374 has been proposed as a
potential candidate immunogen for a universal influenza A
vaccine.10,11
With this background, we decided to incorporate the
NP366–374 epitope (ASNENMETM) into novel GDPs that might
serve as universal flu vaccine candidates. To this end, GDPs
4–5 and 14–17 were synthesized by the previously mentioned
methods A and B (Scheme 1).5 Both approaches rely on two
varieties of click chemistry reactions, namely the Huisgen's
dipolar CuI-catalyzed azide–alkyne cycloaddition (CuAAC)12
and the thiol–ene addition of thiols to maleimides.13 The
GDP systems thus generated, providing multiple presenta-
tions of a conserved and relevant flu epitope, as well as of
Scheme 1 Synthetic routes to glycodendropeptides (GDPs): A) method A and B) method B (where n = number of peptides, and p = number of
maleimides). In method B, final GDPs would be functionalized with n × p copies of the peptide.
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Man residues with expected DC internalization capability,
constitute novel and versatile platforms with enhanced
immunogenic profiles that might eventually find use as syn-
thetic influenza A vaccines.
Results and discussion
The preparation of GDPs by the methods in Scheme 1
required various building blocks (the glycodendron moiety,
two maleimide scaffolds and the peptidic components – the
peptides and MAPs) that were prepared as previously
described.5 Briefly, the nonavalent Man glycodendron 1 was
conveniently constructed by a convergent process that used
pentaerythritol as the core and 1,3-dipolar cycloadditions for
extension; maleimide dendrons 6 and 7 were derived from
bis-2,2′-hydroxymethyl propionic acid (bis-MPA),5 and the
single and multiple peptide modules (2, 3, 8, and 9) were
made by Fmoc solid phase synthesis (SPPS).4,14 All peptides
and MAPs were C-terminal carboxamides of either a
bishomopropargylglycine (Bpg) residue (2–3), providing the
alkyne functionality required for CuAAC (Scheme 1A), or a
Cys residue (8–9) supplying the thiol group for thiol–ene liga-
tion (Scheme 1B). In the MAP syntheses, spacers reported to
enhance the flexibility of the construct and the quality of the
final product were incorporated at all branching points.15 For
MAP 3, the spacer was 6-aminohexanoic acid (Ahx), whereas
8-amino-3,6-dioxaoctanoic acid (O2Oc) was selected for 9. All
peptide components were obtained in homogeneous form
(>95% HPLC), with the MS data consistent with the theoreti-
cal values (Table S1, ESI†).
To access GDPs by method A (Scheme 1), peptide 2 or
MAP 3 was directly conjugated with glycodendron 1 by a sin-
gle CuAAC reaction. The best results were obtained with 1
equiv. of CuSO4·5H2O, 2 equiv. of TBTA ĲTrisĳ(1-benzyl-1H-
1,2,3-triazol-4-yl)methyl]amine) and 4 equiv. of sodium ascor-
bate at room temperature in 1 : 1 Ĳv/v) THF/phosphate
buffer (33 mM, pH 7.4). The reproducibility and reliability of
the conditions enabled the preparation of the final GDPs 4
and 5 (with 9 : 1 and 9 : 4 mannose-to-peptide ratios, respec-
tively), with almost quantitative conversions from starting
materials to final products and in a monodisperse way, as
determined by both analytical RP-HPLC and MS (Table S1,
ESI†). The relatively small synthesis scale translated into only
moderate yields of HPLC-purified products, typically in the
35–50% range.
On the other hand, method B (Scheme 1) required two
synthetic steps to reach the target products. In this approach,
maleimide dendrons 6 and 7 served both to multiply peptide
valency and, by way of the alkyne group at their focal posi-
tions, to enable conjugation with glycodendron moiety 1. In
the first step, peptide 8 or MAP 9, either one featuring a
C-terminal Cys, was chemoselectively ligated with di-Ĳ6) or
tetravalent (7) dendrons by thiol–ene addition in 1 : 2 Ĳv/v)
CH3CN/phosphate buffer (100 mM, pH 7.4). The resulting
dendropeptide intermediates 10–13 were obtained with
almost quantitative conversions and in moderate yields after
RP-HPLC purification. This first step allowed access to a
dendropeptide (13) with up to 16 peptide copies. Although
globally its synthesis involved long reaction times and moder-
ate conversion rates, the end-product was again shown to
be clearly monodisperse by analytical RP-HPLC and MS
(Table S1, ESI†).
Once dendropeptide intermediates (10–13) were available,
the corresponding GDPs (14–17) were readily obtained by
CuAAC-mediated conjugation with glycodendron 1 under the
same conditions set up for method A (Scheme 1). By means
of this strategy, a GDP with a 9 : 16 Man/peptide ratio (17)
was obtained which, to the best of our knowledge, is the larg-
est multivalent and mannosylated peptide system thus far
reported, again obtained as a monodisperse entity as proven
by both HPLC and MS (Table S1, ESI†).
With all the above compounds in hand, we evaluated their
effect on specialized cells of the immune system, such as the
DCs and lymphocytes. To this end, DCs were incubated with
GDPs at different concentrations and the expression of matu-
ration and costimulatory markers (HLA-DR, CD80, CD83 and
CD86) was assessed. The results obtained in these experi-
ments indicated that, at a given GDP concentration of 1 μM,
the expression patterns of HLA-DR, CD80 or CD86 markers
were maintained almost constant regardless of the multi-
valency of the NP366–374 moiety. In contrast, an increase in
CD83 expression was observed with the Ĳ4NP366–374)4–Man9
GDP (17), with the highest peptide multiplicity (16 copies),
one log above the responses observed for any other com-
pound (p < 0.005 for all) (Fig. 1).
Such an increase in Ĳ4NP366–374)4–Man9-induced CD83
expression in DCs may have important implications from an
immunological point of view, since different studies have
demonstrated that CD83, as the characteristic marker of full
DC maturation,16 hence involved in T cell-mediated immune
response,17 is essential for DC biology. The effect observed
with compound 17 might overcome the down-modulation in
Fig. 1 Mean and standard deviation of the maturation index of DCs
expressing HLA-DR, CD80, CD83 and CD86 when compared with their
respective expression in imDCs. The expression of markers was
measured after 48 h of incubation with the GDPs at 10−3 μmol mL−1 or
LPS at 1 mg mL−1 as the positive control. Cells were stained using
specific antibodies against each marker and analysed by flow
cytometry.
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CD83 expression produced upon infection by several viruses,
which reduces the ability of infected DCs to stimulate T
cells.18
The proliferative responses of diverse lymphocyte subpop-
ulations after incubation with GDPs at different concentra-
tions were studied by analysing CD3, CD4, CD8 and CD19
expressions (Fig. 2 and 3).
In the presence of NP366–374-displaying compounds at a
fixed 1 μM concentration, an increase in T lymphocyte (CD3)
proliferative response with peptide multiplicity is observed,
with highest significant values found for Ĳ4NP366–374)2–Man9
(16) and Ĳ4NP366–374)4–Man9 (17). Conversely, B lymphocyte
(CD19) proliferation decreases with multivalency, although
these differences are not significant (Fig. 2).
It is worth noting at this point that, during some infection
processes, the immunological responses induced by viral
agents lead to T cell proliferation, and specifically to CD8 T
cells. In the present case, our data show a significant increase
(p < 0.05) in the proliferative response of both CD4 and CD8
subsets of T lymphocytes (Fig. 3). As observed with CD83
expression, the highest proliferation index (PI) was observed
for the compound with the highest peptide multiplicity,
namely Ĳ4NP366–374)4–Man9 (17). This could be explained by
the fact that, as demonstrated by others, CD83 has an impor-
tant effect in regulating activation of functional T cells.19
Although a much higher PI was observed for CD4 T cells
after incubation with Ĳ4NP366–374)4–Man9 (17) (Fig. 3), the pro-
liferative response seems to be more specific for CD8 T cells,
since relatively higher increases were found for this com-
pound when compared to the effect induced by either pep-
tide or glycodendron alone. These findings agree with those
from other authors who have shown that CD83 expression
directly correlates with the ability to induce specific cytotoxic
T lymphocyte proliferation.18a Taken together, our results
from maturation analysis and proliferative response lead us
to conclude that Ĳ4NP366–374)4–Man9 (17) could be a good vac-
cine candidate, given its effectiveness in inducing complete
DC maturation (CD83 increase), hence a subsequent increase
in specific cytotoxic T lymphocyte proliferation. Further
studies to characterize the immunological response of these
T cell subpopulations are being carried out.
Experimental section
Materials and methods
Fmoc-protected amino acids were from Iris Biotech
(Marktredwitz, Germany). Fmoc-Rink amide ChemMatrix
resin, 2-Ĳ1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium
hexafluorophosphate (HBTU) and N-hydroxybenzotriazole
(HOBt) were from Matrix Innovation (Montreal, Canada). All
other reagents were of the highest quality commercially avail-
able from Sigma-Aldrich (Madrid, Spain). All solvents, includ-
ing HPLC-grade CH3CN, and peptide synthesis-grade DMF,
CH2Cl2, DIEA and TFA were from Carlo Erba-SDS (Sabadell,
Spain). Non-peptide compounds were purified by flash chro-
matography using medium or fine silica gel or by Sephadex
LH20 or G25 (GE Healthcare, Barcelona, Spain) gel filtration.
Thin layer chromatography (TLC) was carried out with pre-
coated F254 silica gel plates (Merck, Darmstadt, Germany).
Flash chromatography was carried out with silica gel 60 (230–
400 mesh) (Macherey-Nagel, Düren, Germany). TLC reaction
monitoring was performed using potassium permanganate,
phosphomolybdic acid, 10% sulfuric acid in methanol or
anisaldehyde as development reagents. Analytical HPLC was
carried out on 4.6 × 50 mm, 3 μm C18 or C8 columns
(Phenomenex, Torrance, CA) with a LC-2010A system
(Shimadzu, Kyoto, Japan). Solvents A and B were 0.045% and
0.036% Ĳv/v) TFA in H2O and CH3CN, respectively. Elution
was performed with linear gradients of solvent B into A over
15 min, at a 1 mL min−1 flow rate, with UV detection at 220
nm. Semi-preparative HPLC was done with a 10 × 250 mm,
10 μm, C18 column (Phenomenex) with a Shimadzu LC-8A
system. Solvents A and B were 0.1% TFA Ĳv/v) in H2O and
CH3CN, respectively. Elution was performed with linear gra-
dients of solvent B into A over 30 min, at a 5 mL min−1 flow
rate, with UV detection at 220 nm. Fractions of adequate
purity (>95%) by analytical HPLC were pooled and lyophi-
lized. Mass spectra were obtained by electrospray ionization
with Esquire 6000 (Bruker), LTQ-Orbitrap XL (Thermo Fisher,
Waltham, MA), Q-Star Pulsar (Applied Biosystems, Carlsbad,
Fig. 2 Proliferation index (PI) of CD3 and CD19 lymphocytes after
treatment with different GDPs (1 μM) or PHA (phytohemagglutinin,
10 μg mL−1) as the positive proliferative control for 6 days at 37 °C
including imDCs as antigen-presenting cells.
Fig. 3 Proliferation index (PI) of CD4 and CD8 lymphocytes after
treatment with different GDPs (1 μM) or PHA (10 μg mL−1) as the
positive proliferative control for 6 days at 37 °C including imDCs as
antigen-presenting cells.
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CA) or LC/MSD-TOF (Agilent Technologies) instruments, or
by MALDI-TOF using a Voyager DE-STR (Applied Biosystems).
Compounds 1, 6 and 7 were synthesized as described before.5
On the other hand, compounds 2–3 and 8–9 were prepared
according to the methodology widely used in our group5
(details are included in the ESI†).
General synthetic protocol for dendropeptide intermediates
To a solution of 0.5 μmol (1 equiv.) of maleimide dendron
(0.24 mg of 6 or 0.5 mg of 7) in CH3CN (400 μL), a solution
of 1.5 equiv. per maleimide group of peptide 8 or MAP 9 in
100 mM phosphate buffer, pH 7.4 (800 μL), was added. To
monitor the reaction progress, aliquots of the mixture were
taken for analytical HPLC and MALDI-TOF MS analysis, and
when no further changes in the HPLC profile were observed
(reaction times range from a few minutes to 24 h, depending
on the steric hindrance), the reaction was stopped by addi-
tion of glacial AcOH. The product was then isolated by pre-
parative RP-HPLC. The target compounds (10–13) were
obtained in homogeneous form (>95%) by analytical HPLC
and were satisfactorily characterized by MS (see Table S1,
ESI†).
General protocol for glycodendropeptide synthesis
0.26 μmol of glycodendron 1 and 0.13 μmol of peptide 2,
MAP 3 or dendropeptide intermediates 10–13 were dissolved
in 100 μL of 3 : 2 Ĳv/v) THF/phosphate buffer (100 mM, pH
7.4). In a separate vial, CuSO4·5H2O (0.13 μmol) was
dissolved in H2O (15 μL) and mixed with a solution of TBTA
(0.26 μmol) in THF (33 μL). Next, this solution was added to
the original mixture followed by 52 μL of sodium ascorbate
(0.52 μmol) in H2O. After stirring for about 30 min at room
temperature (the progression of the reaction was monitored
by analytical RP-HPLC), the reaction mixture was lyophilized,
then purified by semi-preparative RP-HPLC to give target
compounds 4–5 and 14–17 (see Table S1, ESI†).
Generation of monocyte-derived DCs
Fresh peripheral blood mononuclear cells (PBMCs) obtained
from 40 mL of human blood from 10 healthy donors were
used for monocyte purification by means of anti-CD14 micro-
beads following the manufacturer's protocol (Miltenyi Biotec,
Germany). The CD14− fraction was placed in 10% dimethyl
sulfoxide and frozen for a later lymphocyte proliferation test.
To generate DCs, CD14+ monocyte cells were incubated in
complete medium (CM) containing RPMI 1640 medium (Life
Technologies, Invitrogen, USA) supplemented with 10% fetal
calf serum (FCS; Life Technologies, USA), streptomycin (100
μg ml−1), gentamicin (1.25 U mL−1) as well as recombinant
human rhGM-CSF (200 ng mL−1) and rhIL-4 (100 ng mL−1)
(both from R&D Systems Inc., USA) for 5 days at 37 °C and
5% CO2. The resulting immature DCs (imDC) were then
recovered and used in the experiments.
DC maturation
imDCs derived from monocytes were incubated in complete
medium at 105 cells per mL in 96-well plates (Nunc AS,
Roskilde, Denmark) with different GDP concentrations (10−3,
10−4 and 10−5 mM). LPS at 1 mg mL−1 (Sigma) was used as
the positive control and culture media as the negative con-
trol. After 72 h of stimulation at 37 °C in 5% CO2, the DCs
were harvested and their maturation state was assessed by
upregulation of CD80, CD86, and CD83 costimulatory mole-
cules and HLA-DR, using fluorescently labelled monoclonal
antibodies (BD Pharmigen, San Diego, California) in a
FACSCanto II cytometer (BD Biosciences, Milpitas, Califor-
nia). The data were processed with FlowJo (TreeStar Inc.,
Switzerland). The results were expressed as the maturation
index calculated as the ratio between the percentages of the
stimulated DCs compared with the non-stimulated DCs.
Lymphocyte transformation tests (LTTs) by CFSE dilution–
proliferation
For this assay, imDCs were used as antigen-presenting cells;
the CD14 fraction, which included autologous lymphocytes;
and GDPs at 10−3, 10−4 and 10−5 mM concentrations. Autolo-
gous lymphocytes at concentrations of 0.5 to 1 × 107 mL−1
were labeled with 5,6-carboxyfluorescein diacetate
N-succinimidyl ester (CFSE) following the manufacturer's
instructions. A total of 100 μL of CFSE-labeled lymphocytes at
a concentration of 1.5 × 106 mL−1 was cultured in a 10 : 1 ratio
with imDCs at a final volume of 250 μL of complete medium,
in 96-well plates in triplicate, with or without a stimulus,
for 6 days at 37 °C and 5% CO2. PHA at 10 μg mL
−1 (Sigma)
was used as the positive proliferative control and culture
media as the negative control. The proliferation of different
lymphocyte subsets (T cells and B cells) was assessed by
flow cytometry, analysing the percentage of CD3, CD4, CD8
and CD19 cells that show a dim expression of CFSE
(CFSEdim). The results were expressed as the proliferation
index (PI), calculated for each subset as ([% CFSEdim stimu-
lated lymphocytes–lymphocyte–DC]/% CFSEdim unstimulated
lymphocytes).
Ethics statement
The institutional review board “Ethics Committee of Málaga
Hospital” approved the study. These studies were carried out
in accordance with the Declaration of Helsinki. Oral and writ-
ten informed consent for all the diagnostic procedures was
obtained from the subjects before being included in the
study.
Statistical analysis
The maturation and proliferation results after culturing with
the different GDPs were compared with nonparametric analy-
sis for related samples (Wilcoxon test). All reported P values
represent 2-sided tests, with the level of significance set at
the probabilities of p < 0.05.
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Conclusions
Our studies indicate that viral peptides such as NP366–374
displayed in the novel GDPs are recognized by the immuno-
logical system inducing DC maturation and therefore an
increase in the T lymphocyte proliferation. We have found
that this effect is oriented to a higher proliferation for CD8 T
cells, the typical cytotoxic cells in an immunological response
against infectious diseases. These responses are directly
related to peptide valency within the structure.
Moreover, we have found that the activation marker CD83
appears to act as a maturational DC marker directly related
to the proliferative response of CD8 T cells. These promising
results suggest that this marker could be useful in evaluating
candidates suitable to be used as viral vaccines inducing a T
cell cytotoxic response. Further studies are needed to better
characterize the immunological response induced by these
structures.
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